Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

The potential gross proceeds from the warrants, if fully exercised on a cash basis, will be approximately $10.0 million. No assurance can be given that any of the warrants will be exercised. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The securities described above were offered and sold by the Company in a registered direct offering pursuant to a "shelf" regist ...